Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997-1998: Overview and implications for vaccine development

Journal of Clinical Microbiology

Volumn 39, Issue 8, 2001, Pages 2897-2903

  Sacchi, C T ^a   Lemos, A P S ^a   Popovic, T ^a   De Morais, J C ^a   Whitney, A M ^a   Melles, C E A ^a   Brondi, L M G ^a   Monteiro, L M C ^a   Paiva, M V ^a   Solari, C A ^a   Mayer, L W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PORIN A; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERIUM ISOLATION; BRAZIL; ENDEMIC DISEASE; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; SEROTYPE; VACCINATION;

BRAZIL; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MOLECULAR SEQUENCE DATA; NEISSERIA MENINGITIDIS; PORINS; PREVALENCE; SEROTYPING; VARIATION (GENETICS);

BACTERIA (MICROORGANISMS); MENINGOCOCCUS; NEGIBACTERIA; NEISSERIA; NEISSERIA MENINGITIDIS SEROGROUP B; OAT MOSAIC VIRUS;

EID: 0034891472     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.39.8.2897-2903.2001     Document Type: Article

References (42)

1. Definition of meningococcal class 1 outer membrane protein subtyping antigens by monoclonal antibodies
2. Neisseria meningitidis group B sero-subtyping using monoclonal antibodies in whole-cell ELISA
3. Neisseria meningitidis: Vaccines and vaccine candidates
4. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile
5. Immunogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins
6. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age
7. Protective efficacy of a serogroup B meningococcal vaccine in São Paulo, Brazil
8. Structural and evolutionary inference from molecular variation in Neisseria porins
9. Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design
10. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes
11. Vaccines for prevention of meningococcal disease
12. Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults
13. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: A brief survey
14. An integrated molecular and immunological approach towards a meningococcal group B vaccine
15. Comparison of the class 1 outer membrane proteins of eight serological reference strains of Neisseria meningitidis
16. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine
17. Class 1 outer membrane protein of Neisseria meningitidis: Epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology
18. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: Comparison with efficacy
19. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine
20. Epidemic disease due to serogroup C Neisseria meningitidis in São Paulo, Brazil
21. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine
22. Meningococcal disease: Still with us
23. Evaluation of 2 tetravalent (ACYW135) meningococcal vaccines in infants and small children - A clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides
24. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among adults in Iceland
25. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine
26. Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines
27. Ongoing group B Neisseria meningitidis epidemic in São Paulo, Brazil, due to increased prevalence of a single clone of the ET-5 complex
28. Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature
29. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998
30. Meningococcal disease caused by Neisseda meningitidis serogroup B serotype 4 in São Paulo, Brazil, 1990 to 1996
31. Immunogenicity of 2 serogroup B outer membrane protein meningococcal vaccines. A randomized controlled trial in Chile
32. Five structural classes of major outer membrane proteins in Neisseria meningitidis
33. Distribution of Neisseria meningitidis serogroup B serosubtypes circulating in the United States
34. Ribotyping as an additional molecular marker for studying Neisseria meningitidis serogroup B epidemic strains
35. Topology of outer membrane porins in pathogenic Neisseria spp.
36. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein
37. Use of transformation to construct antigenic hybrids of the class 1 outer membrane protein in Neisseria meningitidis
38. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine
39. Human immunoglobulin G subclass immune response to outer membrane antigens in meningococcal group B vaccines
40. Serotyping and serosubtyping of Neisseria meningitidis isolates by co-agglutination, dot-botting and ELISA
41. Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins
42. Immunologic response of a man to group B meningococcal polysaccharide vaccines